The National Science Foundation awarded a $255,981 Small Business Innovation Research Phase I Project Grant to Frezent Biological Solutions Inc. of Valhalla, NY under the Engineering (CFDA 47.041) federal grant program. The grant funds the development of a novel peptide inhibitor of the coronavirus papain-like protease as a prophylactic and antiviral therapeutic for COVID-19, to be administered via inhalation. The Engineering program seeks to improve quality of life and economic strength...
The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...
The National Science Foundation awarded a $256,000 Small Business Innovation Research Phase I Project Grant to White Rock Therapeutics under the Engineering federal grant program (CFDA 47.041). The grant will support development of an ACE2 decoy as a pan-coronavirus therapeutic from January 2022 to December 2022. The Engineering program seeks to improve quality of life and economic strength by fostering innovation and excellence in engineering research. This award will fund initial research...
The National Science Foundation Division of Industrial Innovation awarded MBF Therapeutics Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from January 1, 2022 to December 31, 2022. The grant funds the development of a protective T cell vaccine for SARS CoV-2 (COVID-19). The Engineering program supports innovation, creativity and excellence in engineering research and education to improve quality of life and economic strength. This award furthers those...
Neyroblastgx LLC was awarded a $255,997 Project Grant from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program. The grant will support the company's research efforts to genetically engineer dendritic cells to activate T cells specific to the SARS-CoV-2 spike protein, with the goal of developing a novel approach to treating COVID-19. The research is expected to be conducted between April 2021 and December 2022. The NSF Technology, Innovation, and...
Altigg Therapeutics, Inc. was awarded a $255,595 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation's Engineering program (CFDA 47.041) for the period of April 1, 2021 through March 31, 2022. Under this award, Altigg Therapeutics will develop a platform for the rapid discovery of human antibodies as therapeutics for infectious diseases such as COVID-19. The NSF Engineering program seeks to improve quality of life and economic strength through...
The National Science Foundation Division of Industrial Innovation awarded a $255,908 Project Grant to Verisim Life, Inc. under the Engineering (47.041) federal grant program. The grant supports Verisim Life's efforts to rapidly repurpose and translate COVID-19 therapeutics using an AI-based biosimulation platform. Specifically, the company will apply its platform to research multi-target therapies involving angiotensin-converting enzyme 2 and calcium pathways, which could help combat the...
Nanored LLC received a $246,731 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the development of a novel SARS-CoV-2 virus-like particle optimized to deliver shRNA therapeutics from March 1, 2021 through April 30, 2022. The grant aims to prevent and treat COVID-19 infection through a delivery method utilizing virus-like particles to transport self-amplifying short hairpin RNA molecules into cells. The funding will...
Eradivir Inc. received a $256,000 Small Business Technology Transfer (STTR) Phase I Project Grant from the National Science Foundation to develop a therapeutic molecule for COVID-19. Under the grant, awarded February 15, 2021 for the period through January 31, 2022, Eradivir will conduct research at its facilities in West Lafayette, Indiana under the NSF's Engineering program (CFDA #47.041). The Engineering program seeks to improve quality of life and economic strength through fostering...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...